In addition, there was a retrospective research conducted to identify the characteristics of patients who may respond to anti-PD-1 inhibitors therapy for EGFR-mutant NSCLC, results of which revealed that patients who had responded to EGFR TKIs as front line treatment for more than ten months exhibited a significantly shorter response duration to anti-PD-1 inhibitors compared to those responded for less than ten months (PFS of ICI:1.6 vs. 1.9 months; HR:2.54; 95% CI, 1.26–5.12, P = 0.009). This evidence concerns the gene EGFR and non-small cell lung carcinoma.